How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN
Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.
Pharma & Biotech
Pharma & Biotech
Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Pharma & Biotech
Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Pharma & Biotech
Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
Pharma & Biotech
Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?
Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.
Pharma & Biotech
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.
Pharma & Biotech
Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.
Pharma & Biotech
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
Pharma & Biotech
Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Pharma & Biotech
Takeda and Protagonist near FDA decision on novel PV therapy rusfertide
FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.